Abstract
Background Oral immunotherapy is an emerging therapy currently under investigation for the treatment of food allergy [1]. Underlying mechanisms are thought to involve a switch in the food specific T cell response from Th2 to either Th1, Tr1 and/or Treg. It is unknown whether this change in response results from re-education of existing pathological food-specific T cells or from their replacement by new healthy T cells (change of guard hypothesis).
Highlights
Oral immunotherapy is an emerging therapy currently under investigation for the treatment of food allergy [1]
Peripheral blood mononuclear cells (PBMCs) from three subjects undergoing rush oral immunotherapy in a previous trial [2] and three control subjects on avoidance diet were cultured with peanut extract at baseline and at 9 and 18 months
Carboxyfluorescein succinimidyl ester (CFSE)-low peanut proliferating T cells were isolated by fluorescence-activated cell sorting (FACS) and T cell receptor (TCR) analysis was performed
Summary
Oral immunotherapy is an emerging therapy currently under investigation for the treatment of food allergy [1]. Underlying mechanisms are thought to involve a switch in the food specific T cell response from Th2 to either Th1, Tr1 and/or Treg. It is unknown whether this change in response results from re-education of existing pathological food-specific T cells or from their replacement by new healthy T cells (change of guard hypothesis)
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
